Comparison of Anesthetic Efficacy OF 2% Lidocaine Inferior Alveolar Nerve (IANB) Block Versus Pri… (NCT07409896) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Comparison of Anesthetic Efficacy OF 2% Lidocaine Inferior Alveolar Nerve (IANB) Block Versus Primary Buccal Infilteration With 4% Articaine in Symptomatic Irreversible Pulpitis(SIP) IN Mandibular First Molars
Pakistan330 participantsStarted 2026-02-01
Plain-language summary
This randomized controlled trial aims to compare the anesthetic efficacy of 2% lignocaine administered through an inferior alveolar nerve block (IANB) in one group of participants with 4% articaine delivered via primary buccal infiltration in other group in patients with symptomatic irreversible pulpitis in mandibular first molars.
Who can participate
Age range
18 Years – 55 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Systemically healthy patients classified as ASA I, aged 18-55 years.
* Permanent mandibular first molar tooth requiring endodontic therapy.
* Diagnosed with symptomatic irreversible pulpitis without swelling or sinus.
* Normal periapical radiographic appearance (no evidence of periapical pathology).
* Moderate pain as assessed by the Heft-Parker VAS (\>54 mm and \<114 mm).
* Lingering pain or prolonged response to cold testing (lasting more than 10 seconds).
* Positive response to electric pulp testing.
* Outcome assessed must be pulpal anesthesia
Exclusion Criteria:
* • Pregnant or lactating mothers.
* Teeth with reversible pulpitis, previously treated, or with calcified canals.
* Teeth with severe periodontal disease or periapical radiolucency.
* Patients who have taken analgesics or anti-inflammatory drugs within 6 hours before the treatment visit.
* Patients on medications that could potentially interact with the anesthetic solution (e.g., antihypertensives, anticoagulants).
* History of allergy to 4% articaine, lidocaine, or epinephrine.
* Systemic diseases, immunocompromised states, or significant anxiety/mental health disorders.
* History of vasovagal syncope on local anesthetic administration
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Anesthetic efficacy
Timeframe: 1 hour after administration of anesthetic agent
Trial details
NCT IDNCT07409896
SponsorArmed Forces Institute of Dentistry, Pakistan
Sponsor typeOTHER
Study typeINTERVENTIONAL
Primary completion2026-08-01
Contact for this trial
Dr. Sadia Shehzadi Dr. Sadia Shehzadi, BDS,FCPS(PG3)